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Abstract There are three central ideas contained within this
review. Firstly, growth factor-stimulated signaling is not
restricted to a 30^60 min window, but occurs at a much later
time as well. Secondly, the second wave of signaling overlaps
temporally with the cell cycle program and may be directly
responsible for engaging it. Thirdly, the G1 to S interval appears
to encompass two distinct phases of the cell cycle, during which
the coordinated activation of distinct sets of signaling enzymes
drives cell cycle progression. Each of these concepts is likely to
initiate new investigation and hence provide additional insight
into the fundamental question of how growth factors drive cell
proliferation. ß 2001 Federation of European Biochemical So-
cieties. Published by Elsevier Science B.V. All rights reserved.
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1. The cell cycle
1.1. The G0 to S interval is the only portion of the cell cycle
that is regulated by growth factors
When plated at low cell density in serum-containing me-
dium, cultured cells move through four phases of the cell
cycle: G1, S, G2 and M (Fig. 1). Each of these phases is
regulated by the coordinated action of kinases and proteases
[1,2]. When deprived of serum, cells continue to cycle until
they complete mitosis, whereupon they exit into the G0 state
[3,4]. These cells can be reintroduced into the cell cycle by the
re-addition of serum or puri¢ed growth factor. The mitogen
must be present until the R point (Fig. 1) which is several
hours prior to the transition between G1 and S [4,5]. Thus
in serum-deprived cells, all of the growth factor-stimulated
events that are necessary for completion of one round of
the cell cycle occur before the R point. Furthermore, growth
factors are not needed at later times to complete the other
stages of the cell cycle.
Fig. 2 outlines the cell cycle events that constitute the G1
cell cycle program. Phosphorylation of the retinoblastoma
(Rb) protein is the current molecular de¢nition of the R point
[5]. At least two classes of G1 cyclin-dependent kinases (Cdks)
collaborate to fully phosphorylate Rb, which results in the
release of the E2F family of transcription factors [6]. This
class of transcription factors initiates subsequent events nec-
essary for transition through the other phase of the cell cycle,
even in the absence of serum. Consequently, the mitogenic
potential of growth factors is intrinsic to their ability to pro-
mote phosphorylation of Rb.
1.2. Elements of the cell cycle program that are regulated by
signaling enzymes
Growth factors promote phosphorylation of Rb by regulat-
ing the activity of the G1 Cdks. This involves promoting the
synthesis and stability of cyclin subunits, as well as decreasing
the levels of Cdk inhibitors (Fig. 2B). For instance, growth
factor-dependent activation of the Ras/Erk pathway increases
cyclin D1 mRNA [7^13]. Furthermore, the PI3K/Akt pathway
stabilizes the cyclin D1 proteins. At least in some cell types,
activation of Akt inhibits glycogen synthase kinase 3L
(GSK3L)-dependent phosphorylation of cyclin D1, and there-
by prevents its degradation via the proteasomal pathway [14^
17]. Others have also implicated PI3K/Akt in cyclin D1 accu-
mulation, although the mechanism of action does not appear
to be in stabilization of the cyclin D1 protein, and appears to
involve transcriptional activation of cyclin D1 [18]. Accumu-
lation of cyclin D1 results in the assembly of cyclin D1/Cdk4,6
complexes [7]. Growth factor-dependent elimination of Cdk
inhibitors such as p27Kip1 proceeds through a PI3K-dependent
pathway and is essential for transition through G1 and into S
phase [18^20]. Recent studies indicate that Akt acts down-
stream of PI3K to phosphorylate members of the forkhead
family of transcription factors such as AFX/FKHR [21^25].
When phosphorylated these transcription factors move out of
the nucleus and thereby cease driving transcription of p27Kip1
[26]. Hence growth factors promote Cdk activity by increasing
levels of cyclins and decreasing the levels of Cdk inhibitors.
Active cyclin D1/Cdk4,6 partially phosphorylates Rb,
which begins to release the E2F family members (Fig. 2A).
Free E2F promotes the transcription and consequent accumu-
lation of a second cyclin, cyclin E, which couples with the
Cdk2 kinases. The appearance of cyclin E/Cdk2 has at least
three functional consequences (Fig. 2B). Firstly, it acts in
collaboration with cyclin D1/Cdk4,6 to titrate p27Kip1 levels.
Secondly, cyclin E/Cdk2 phosphorylates p27Kip1 and hence
targets it for ubiquitination and degradation via the protea-
some [27,28]. Thirdly, cyclin E/Cdk2 further phosphorylates
Rb, which fully activates the E2F family (Fig. 2A).
The role of p27Kip1 and a second Cdk inhibitor, p21Cip1, has
become more complicated with the appreciation of an addi-
tional function for these proteins. They not only block Cdk
activity, but p27Kip1 and p21Cip1 are also instrumental in the
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assembly of the cyclin D1/Cdk complexes [29,30] (Fig. 2).
Furthermore, p21Cip1 and p27Kip1 are components of the ac-
tive cyclin D1/Cdk4,6 enzyme [30]. Finally, there appears to
be a di¡erence between cyclin D1/Cdk4,6 and cyclin E/Cdk2
in the way they are regulated by p27Kip1. In contrast to the
readily detectable kinase activity of the cyclin D1/Cdk4,6/
p27Kip1 complex, when p27Kip1 joins the cyclin E/Cdk2 com-
plex, it extinguishes kinase activity [31,32]. Thus the Cdk in-
hibitors promote activation of cyclin D1/Cdk4,6, and inhibit
the activity of cyclin E/Cdk2. Further studies will be required
to resolve the apparent paradox regarding how the Cdks both
promote and inhibit [33] cyclin D1/Cdk4,6 activity.
In summary, activation of the Ras/Erk or PI3K/Akt path-
ways results in an increase in cyclin D1 mRNA, and some
investigators ¢nd that the PI3K/Akt pathway stabilizes the
cyclin D1 protein. In addition, growth factors suppress
p27Kip1 levels, in a pathway that also involves PI3K. Thus
cyclin D1 and p27Kip1 are two elements of the cell cycle pro-
gram that appear capable of receiving input from growth
factor-dependent signaling. Since full phosphorylation of
Rb, i.e. passing the R point, requires the coordinated input
of several distinct components of the cell cycle program, there
may be additional points of the cell cycle program at which
growth factor-dependent signaling makes other essential con-
tributions.
2. Most of the well-studied growth factor-initiated signaling
events occur many hours before the cell cycle program
2.1. Growth factor-stimulated signaling is transient
In acutely stimulated cells there are two themes to the
signaling events: phosphorylation/dephosphorylation and
changes in the subcellular location. For instance, tyrosine
phosphorylation of the PDGFR at the appropriate tyrosine
residues enables stable association with PI3K [34,35]. While
this relocates PI3K from the cytoplasm to a juxtamembrane
location, the location of its lipid substrate, accumulation of
active Ras is also needed for activation of PI3K [36^38]. PI3K
generates second messengers (PI-3,4-P2 and PI-3,4,5-P3),
which are the activators for downstream signaling enzymes
such as Akt and PKC family members [39,40]. These Ser/Thr
kinases are some of the enzymes capable of relaying the
mitogenic signal along a cascade that appears to be part of the
network that integrates signals, which emanate from integrins
and the sensors of cell shape and cytoskeletal integrity.
While the exact nature of this overall signaling network is
far from understood, it is clear that the initial phase of growth
factor-stimulated signaling events does not persist much lon-
ger than 60 min. For instance, PI3K products accumulate
within minutes of PDGF stimulation, and then return to
near basal levels by 30 min [41^43]. There appears to be a
variety of reasons why signaling subsides, one of which relates
to the half-life of the growth factor receptor. One of the pro-
teins that is phosphorylated in response to growth factors is
c-Cbl, a protein that promotes internalization and/or degra-
dation of growth factor receptors [44]. Enzymes such as
PTEN, a phosphatase capable of dephosphorylating and
hence metabolizing the PI3K lipid products, may also contrib-
ute to the decline of cellular PI3K lipid products [45]. Other
well-characterized mechanisms to extinguish signaling include
the rapid expression of new genes that counteract the signal-
ing enzymes. MKP-1 is a phosphatase that dephosphorylates
and hence inactivates Erk family members [46]. In resting cells
MKP-1 levels are low, and then rise quickly following mito-
genic stimulation.
In summary, growth factors trigger a rapid burst of signal-
ing events that subsides even in the continuous presence of
growth factor. Receptor internalization and degradation, as
well as the appearance of enzymes, which antagonize the sig-
naling enzymes, are some of the ways in which the cell silences
the growth factor-initiated signaling cascade.
2.2. How do growth factor-stimulated signaling events engage
the cell cycle program?
If the ¢rst wave of growth factor-dependent signaling is
complete within 60 min, then what triggers the cell cycle pro-
gram, which begins roughly 7^9 h after exposure to PDGF?
Since the early signaling events induce the expression of many
new genes, including those that are involved in cell prolifer-
ation, perhaps it is the products of these genes that are re-
sponsible for engaging the cell cycle program. If this were
indeed the case, then exposure to growth factor for 1^2 h,
which is su⁄cient to induce the immediate early genes, would
also be su⁄cient to drive cells into S phase. However, ¢bro-
blasts require 8^10 h of continuous exposure to growth factor
to get past the R point [4,47,48]. Hence the early burst of
signaling is insu⁄cient for cell cycle progression, and there
must be additional inputs that the growth factor makes at
latter time points. Insight into this long-standing question
has come from a number of labs demonstrating that there
are requirements for signaling enzymes and/or signaling events
well beyond the well-studied early burst of signaling.
Fig. 1. Only a small portion of the cell cycle is regulated by growth factors. Cells that have been deprived of serum or growth factors exit the
cell cycle and enter into the G0 state. Growth factors promote exit from G0, and cells will commit to one round of the cell cycle if growth fac-
tors are present up to the R point. An important component of the R point is phosphorylation of Rb, which is further outlined in Fig. 2.
Once past the R point, most cells will continue through the other stages of the cell cycle, even if the growth factor is removed from the culture
medium.
FEBS 24563 14-2-01
S.M. Jones, A. Kazlauskas/FEBS Letters 490 (2001) 110^116 111
3. Growth factor-stimulated signaling beyond the ¢rst 60 min
3.1. Microinjection studies indicate that signaling enzymes are
needed well beyond the ¢rst 60 min
One approach to investigate the importance of a signaling
enzyme for growth factor-dependent mitogenesis is to elimi-
nate it by microinjection of a neutralizing antibody directed
against the signaling enzyme, and assay the e¡ect on S phase
entry. The Stacey lab used this approach, and learned that
activated Ras is required for entry into S phase [49]. These
studies were performed by pre-injecting cells with the anti-
body, and then stimulating with the mitogen. They indicated
that Ras was important at some point, but did not specify
when. By injecting the antibody after exposing cells to the
growth factor it has been possible to begin to assess when
the signaling enzyme is contributing to mitogenic signaling.
Blocking Ras, SHP-2 or PI3K hours after the initial wave
of growth factor-dependent signaling prevented growth fac-
tor-dependent entry into S phase [50^54]. These studies
strongly suggested that signaling enzymes are important for
mitogenic signaling at times beyond the initial burst of signal-
ing.
Fig. 2. The G1 cell cycle program. A: Full phosphorylation of Rb requires the coordinated action of two Cdks, and results in the release of
the E2F family of transcription factors. Growth factors promote the accumulation of cyclin D1, which forms a complex with either Cdk4 or 6.
The cyclin D1/Cdk4,6 complex phosphorylates Rb releasing a small amount of E2F, which in turn drives the formation of cyclin E. The cyclin
E/Cdk2 complex further phosphorylates Rb, releasing more E2F. The E2F family of transcription factors promotes transcription of genes that
initiate the transition into S phase. B: Role of p27Kip1 in the cell cycle program. p27Kip1 and p21Cip1 (not shown) promote assembly of the cy-
clin D/Cdk4,6 complex. p27Kip1 inhibits the kinase activity of both of the cyclin/Cdk complexes, and appears to be more potent towards cyclin
E/Cdk2. There are at least three ways by which p27Kip1 is neutralized. Growth factors suppress the synthesis of p27Kip1 protein; cyclin E/Cdk2
phosphorylates p27Kip1 and targets it for degradation; cyclin D/Cdk4,6 sequester p27Kip1. GSK3 is glycogen synthase kinase 3L ; AFX/FKHR
is the forkhead transcription factor.
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3.2. Two waves of signaling in cells treated continuously with
growth factors
To directly investigate the idea that signaling is occurring at
later time points, a number of investigators began to monitor
signaling events in cells that had been treated with growth
factors for longer times. For instance, several groups have
reported biphasic activation of Ras in serum-stimulated
NIH 3T3 cells [18,55]. The level of active Ras peaks within
10 or 30 min, recedes, and then peaks again 2^6 or 2^4 h later.
Similarly, PDGF triggers two waves of PI3K and PKC activ-
ity in HepG2 cells, an early and then a late phase; the late
phase being 3^7 h after the addition of growth factor [42,56].
These studies demonstrate that there are two waves of activity
for a variety of signaling systems, and raise a number of
interesting questions.
For instance, how are these two waves of activity regu-
lated? The ¢rst wave of activity has been studied at length,
as it is the one observed in acutely stimulated cells. As out-
lined in the sections above, there is a wealth of information
regarding the mechanism by which signaling enzymes such as
Ras and PI3K are activated in acutely stimulated cells. In
contrast, virtually nothing is known regarding the molecular
events by which the second wave of activity appears. Whether
the mechanisms by which the signaling enzymes are activated
during the ¢rst and second wave of signaling are comparable
awaits further investigation.
3.3. The second wave of signaling is required for cell
proliferation
An additional question that arises from the observation
that there are two waves of enzymatic activity is the relative
contribution of each wave to growth factor-driven mitogene-
sis. The second wave of signaling is required for S phase entry,
at least in the case of Ras and PI3K, since injecting neutraliz-
ing antibodies directed against these proteins blocked cell
cycle progression. Additional approaches have also found
that the second wave of PI3K, PKC and Ras activity is essen-
tial for cells to respond mitogenically to growth factors
[20,42,54,56].
Some of the signaling enzymes make unequal contributions
to the mitogenic response during the ¢rst and second waves of
signaling. In the case of PI3K, and certain PKC family mem-
bers, only the second wave of activity was required for
PDGF-dependent entry into S phase [42,56]. The addition
of pharmacological inhibitors at times corresponding to the
second wave of activity attenuated PDGF-dependent DNA
synthesis. The inhibitors had no e¡ect if they were used to
block only the ¢rst wave of PI3K or PKC activity. Similarly,
adding synthetic PI3K lipid products or diacylglycerol
(DAG), an activator of certain PKC family members, rescued
PDGF-dependent DNA synthesis, but only when they were
added at times corresponding to the second wave of activity.
Adding the PI3K lipid products or DAG simultaneously with
PDGF failed to promote PDGF-dependent DNA synthesis in
this system. Hence, although PI3K and PKCs are activated
during the ¢rst wave of PDGF-induced signaling, their acti-
vation at this time is dispensable for the DNA synthesis re-
sponse. It is likely that they are contributing to other PDGF-
dependent cellular responses such as chemotaxis and survival
[57^59].
4. The ‘two-wave’ hypothesis for how signaling and cell cycle
progression are linked
4.1. Growth factor-dependent signaling is not needed
continuously during the interval between G0 and the R
point
Because the initial wave of signaling occurs so much in
advance (7^9 h) of even the ¢rst element of the cell cycle
Fig. 3. The discontinuous stimulation assay. Serum-arrested NIH 3T3 cells were pulsed with PDGF for 30 min, the cells were then acid-washed
and placed into medium containing 0.1% FBS. 7.5 h later PDGF and [3H]thymidine were added and the cells were harvested at the 18 h time
point. S phase, as measured by an increase in the incorporation of [3H]thymidine, is between 12 and 26 h in these cells.
Fig. 4. The two-wave hypothesis for how signaling and cell cycle
progression are linked. Exposure of quiescent (G0) cells to growth
factors initiates many signaling events. Of these, activation of
MEK/Erk and elevation of c-Myc are su⁄cient to drive cells out of
G0 and through the early portion of G1 (G1E). Further progression
through G1 requires a second input of growth factor. The timing of
this requirement overlaps with the second wave of signaling, and in-
itiates the cell cycle program. This occurs in the late phase of G1,
and is termed G1L. PI3K is one of the signaling enzymes that are
activated at this later time and capable of engaging the cell cycle
program. As outlined in Fig. 2, the cell cycle program results in
phosphorylation of Rb, transition past the R point and commitment
to one round of the cell cycle. At least some of the events that oc-
cur in G1L have been well-de¢ned, i.e. the cell cycle program. In
contrast, the molecular events that are necessary for transition
through G1E are just beginning to be identi¢ed.
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program, these early signaling events do not appear to be
directly responsible for engaging components of the cell cycle
program. In contrast, the second wave of signaling overlaps
with the cell cycle program, and hence may be directly trigger-
ing the cell cycle program. This hypothesis has been di⁄cult
to test because the second wave of signaling requires pro-
longed exposure to PDGF, which probably triggers events
other than those required for cell cycle progression. We
have recently employed a discontinuous stimulation assay
(Fig. 3) to evaluate the possibility that a late phase of signal-
ing is responsible for engaging the cell cycle program [60].
Two 30 min pulses of PDGF are su⁄cient to drive NIH
3T3 cells into S phase and through the rest of the cell cycle.
Furthermore, the kinetics of S phase entry as well as events of
the cell cycle program proceeded comparably in cells treated
continuously or discontinuously with PDGF. The ¢rst pulse
de¢ned the start of the experiment, and the ideal time for the
second pulse was 8 h. Importantly, the ¢rst pulse was insu⁄-
cient to initiate the cell cycle program, whereas that second
pulse of growth factor rapidly engaged the cell cycle program,
i.e. cyclin D1 protein was detectably elevated within 1 h of the
second pulse. Hence the early burst of signaling made the cells
able to engage the cell cycle program, which was triggered by
the second pulse of PDGF. As illustrated in Fig. 4, we are
proposing the terms early G1 (G1E), and late G1 (G1L) for
these portions of G1.
4.2. Di¡erent sets of signaling enzymes mediate progression
through G1E and G1L
The subdivision of the G0 to S interval is also supported by
the ¢nding that di¡erent sets of signaling enzymes mediate
transition through G1E and G1L [60]. Of the many signaling
events triggered by the ¢rst pulse of PDGF, activation of
MEK and elevation of c-Myc were su⁄cient for transition
through G1E. MEK activity was also necessary during the
second pulse of growth factor-driven signaling. In contrast,
synthetic PI3K lipid products failed to drive cells through
G1E, but were su⁄cient for transition through G1L. These
¢ndings indicate that traversing the two segments of the G0
to S interval requires non-identical sets of signaling enzymes.
Finally, transition through G1E is a prerequisite for engaging
the cell cycle program, which is the consequence of subse-
quent exposure to growth factor.
4.3. A common signaling cascade is used by many mitogens
Many agents are mitogenic, and while they interact with
speci¢c and unique cell surface receptors, it is possible that
they eventually engage a common cascade to promote cell
cycle progression. This idea has been investigated with the
discontinuous stimulation assay described above. Six mitogens
were tested for their ability to substitute for PDGF during the
¢rst or second pulse, i.e. to drive cells through G1E or G1L
[60]. Four of the six agents (fetal bovine serum (FBS), FGF,
PDGF and lysophosphatidic acid (LPA)) were completely in-
terchangeable. Any of the four agents given at the ¢rst pulse,
followed by any one of the four in the second pulse drove cells
into S phase. These ¢ndings imply that there is a common
signaling cascade that can be accessed by a variety of receptor
tyrosine kinases, as well as G protein-coupled receptors.
Unlike the four mitogens described above, EGF and insulin
failed to drive cells through G1E. However, these agents were
biologically active, as EGF or insulin promoted progression
through G1L. Cells that had been brought through G1E by a
pulse of FBS, bFGF, LPA or PDGF were driven into S phase
when EGF or insulin was used for the second pulse. Hence
the cells have receptors for EGF and insulin, and these recep-
tors access the necessary events to engage the cell cycle pro-
gram and propel the cells through G1L and into S phase. The
failure of EGF and insulin to promote transition through G1E
could be because a 30 min pulse of these two growth factors
triggers a much less robust activation of Erk and elevation of
c-Myc, as compared with the four agents that drive cells
through G1E [60]. These ¢ndings indicate that there is a com-
mon signaling pathway that is utilized by many di¡erent
agents. Furthermore, we predict that any agent capable of
activating Erk and elevating c-Myc during the ¢rst wave of
signaling, followed by an elevation of PI3K products 8 h later
will be su⁄cient to drive NIH 3T3 cells into S phase.
Several lines of evidence indicate that the signaling path-
ways discussed above are not the only ones that are capable of
engaging the mitogenic cascade. Cells that are nullizygous for
c-myc are viable, although they proliferate more slowly than
control cells [61]. Similarly, DAG is as e¡ective as PI3K lipid
products in rescuing PDGF-dependent DNA synthesis when
added to cells at times that appear to correspond to G1L
[42,56]. Hence it is likely that there will be additional enzymes
identi¢ed that are capable of accessing this common mitogenic
cascade.
4.4. Revisiting competence and progression
Using subsaturating concentrations of growth factors,
Pledger, Stiles, Antoniades, and Sher demonstrated that in
Balb/c 3T3s cell cycle progression required the input of two
di¡erent types of factors [62^64]. Growth factors such as
PDGF made the cells competent, but did not drive them
into S phase. A second type of growth factor, such as insulin,
was required for progression of the competent cell into S
phase. Once competent, the cells remained in this state for
many hours, and such a cell entered S phase 12^14 h after
the addition of a progression factor [4].
We were interested in determining how the discontinuous
stimulation assay related to the competence/progression con-
cept. To this end we adapted the discontinuous stimulation
assay to Balb/c 3T3 cells. When PDGF was used for the ¢rst
and second pulses, there was very little DNA synthesis in-
duced. Insulin at the ¢rst and second pulses, or insulin ¢rst
and then PDGF, also failed to induce entry into S phase. In
contrast, PDGF followed by insulin during the second pulse
triggered robust DNA synthesis [60]. Thus it appeared that we
were observing the previously reported competence/progres-
sion phenomenon with the discontinuous stimulation assay.
Analyzing the time at which cells synthesized DNA further
supported the idea that the Balb/c 3T3 cells were behaving
along the competence/progression guidelines. When the com-
petence and progression factors were used during the ¢rst and
second pulses, respectively, the cells entered S phase during
the 22^32 h window. In contrast, DNA synthesis was ob-
served in the 12^22 h window when a complete set of mito-
gens (PDGF and insulin or FBS) was used during both pulses.
The delay in the onset of DNA synthesis was because the
competent cells did not begin to traverse the G0 to S interval
until receiving the progression factor at the 8 h time point.
The presence of both the competence and progression factors
during the ¢rst pulse enabled the cells to become competent
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and to begin traversing G1 right away. This suggests that
under these experimental conditions, cells become competent
very quickly.
Finally, we determined whether the competence/progression
phenomenon was intrinsic to the ¢rst or second pulse in the
discontinuous stimulation assay. Adding a complete set of
mitogens during the ¢rst pulse was insu⁄cient to drive cells
into S phase. When such cells were given a second pulse of
either PDGF or insulin, they initiated DNA synthesis during
the early window. This indicated that the complete mitogens
drive cells only through the ¢rst segment of the G0 to S
interval. From this point either a progression or competence
factor promotes transition through the rest of G1 and into S
phase. Hence it appears that competence is a component of
the events that involve traversing the ¢rst segment of the G0
to S interval.
We have also applied the discontinuous stimulation assay to
HepG2 cells. The maximal DNA synthesis response was ob-
served when PDGF was given at the ¢rst and second pulses
[60]. Hence PDGF was a complete mitogen instead of a com-
petence factor, and in this regard the HepG2 cells are more
similar to the NIH 3T3 cells than the Balb/c 3T3s. These
¢ndings further support the idea that the competence/progres-
sion phenomenon is not universal to all cell types. Finally,
there are at least three cell lines that can be e⁄ciently driven
into S phase by discontinuous instead of continuous exposure
to growth factors.
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